The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.
An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had previously been
The European Commission (EC) has approved a combination of Bristol Myers Squibb’s (BMS) Opdivo with Ipsen’s Cabometyx for the first-line treatment of advanced renal cell carcinoma (RCC) – the
BMS releases new data from its phase 3 CHECKMATE-648 study. In interim results released yesterday, Bristol Myers Squibb's (BMS) Opdivo, a PD-(L) 1 checkpoint inhibitor showed improved survival
Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting.
The first-line approval for Keytruda gives it an advantage over rival checkpoint inhibitor Opdivo (nivolumab) from Bristol Myers Squibb (BMS).
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...